Patients with giant cell arteritis have a greater risk for aortic complications than those with polymyalgia rheumatica.

The table below is a review of notable updates that occurred in April 2025 for investigational products in development.

Immunological tests can differentiate proliferative from non-proliferative lupus nephritis, but anti-C1q antibodies and urinary erythrocytes have the best predictive power to dist ...

Ultrasound-guided minimally invasive tenosynovial biopsy is a feasible, safe, and well-tolerated technique among patients with different stages of RA.

Early-life mutagenic exposure to colibactin-producing bacteria may be associated with the increased incidence of early-onset colorectal cancer.

Machine learning has enabled spatiotemporal mapping of the four stages of the evolution of inflammatory bowel disease (IBD).

Here's a new summary of all the drugs in the pipeline currently being evaluated for the treatments of vasculitis.

Among patients with acute LBP, use of nonpharmacologic therapy was associated with reduced risk for overdose-related hospitalizations.

The FDA has approved Selarsdi (ustekinumab-aken) as interchangeable to the reference product Stelara (ustekinumab).

Metformin and SGLT2 inhibitors are associated with similar rates of incident gout among patients with type 2 diabetes.

Hospital-onset antimicrobial-resistant infections increased across US hospitals during and beyond the COVID-19 pandemic.

The Food and Drug Administration (FDA) has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients aged 12 years and older who are ...